148 related articles for article (PubMed ID: 27216773)
1. Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML.
Botezatu L; Michel LC; Helness A; Vadnais C; Makishima H; Hönes JM; Robert F; Vassen L; Thivakaran A; Al-Matary Y; Lams RF; Schütte J; Giebel B; Görgens A; Heuser M; Medyouf H; Maciejewski J; Dührsen U; Möröy T; Khandanpour C
Exp Hematol; 2016 Aug; 44(8):713-726.e14. PubMed ID: 27216773
[TBL] [Abstract][Full Text] [Related]
2. Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS).
Xie X; Frank D; Patnana PK; Schütte J; Al-Matary Y; Liu L; Wei L; Dugas M; Varghese J; Nimmagadda SC; Khandanpour C
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008835
[TBL] [Abstract][Full Text] [Related]
3. GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome.
Botezatu L; Michel LC; Makishima H; Schroeder T; Germing U; Haas R; van der Reijden B; Marneth AE; Bergevoet SM; Jansen JH; Przychodzen B; Wlodarski M; Niemeyer C; Platzbecker U; Ehninger G; Unnikrishnan A; Beck D; Pimanda J; Hellström-Lindberg E; Malcovati L; Boultwood J; Pellagatti A; Papaemmanuil E; Le Coutre P; Kaeda J; Opalka B; Möröy T; Dührsen U; Maciejewski J; Khandanpour C
Exp Hematol; 2016 Jul; 44(7):590-595.e1. PubMed ID: 27080012
[TBL] [Abstract][Full Text] [Related]
4. Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.
Frank D; Patnana PK; Vorwerk J; Mao L; Gopal LM; Jung N; Hennig T; Ruhnke L; Frenz JM; Kuppusamy M; Autry R; Wei L; Sun K; Mohammed Ahmed HM; Künstner A; Busch H; Müller H; Hutter S; Hoermann G; Liu L; Xie X; Al-Matary Y; Nimmagadda SC; Cano FC; Heuser M; Thol F; Göhring G; Steinemann D; Thomale J; Leitner T; Fischer A; Rad R; Röllig C; Altmann H; Kunadt D; Berdel WE; Hüve J; Neumann F; Klingauf J; Calderon V; Opalka B; Dührsen U; Rosenbauer F; Dugas M; Varghese J; Reinhardt HC; von Bubnoff N; Möröy T; Lenz G; Batcha AMN; Giorgi M; Selvam M; Wang E; McWeeney SK; Tyner JW; Stölzel F; Mann M; Jayavelu AK; Khandanpour C
Blood; 2023 Dec; 142(25):2175-2191. PubMed ID: 37756525
[TBL] [Abstract][Full Text] [Related]
5. GFI1 as a novel prognostic and therapeutic factor for AML/MDS.
Hönes JM; Botezatu L; Helness A; Vadnais C; Vassen L; Robert F; Hergenhan SM; Thivakaran A; Schütte J; Al-Matary YS; Lams RF; Fraszscak J; Makishima H; Radivoyevitch T; Przychodzen B; da Conceição Castro SV; Görgens A; Giebel B; Klein-Hitpass L; Lennartz K; Heuser M; Thiede C; Ehninger G; Dührsen U; Maciejewski JP; Möröy T; Khandanpour C
Leukemia; 2016 Jun; 30(6):1237-45. PubMed ID: 26847026
[TBL] [Abstract][Full Text] [Related]
6. A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia.
Khandanpour C; Thiede C; Valk PJ; Sharif-Askari E; Nückel H; Lohmann D; Horsthemke B; Siffert W; Neubauer A; Grzeschik KH; Bloomfield CD; Marcucci G; Maharry K; Slovak ML; van der Reijden BA; Jansen JH; Schackert HK; Afshar K; Schnittger S; Peeters JK; Kroschinsky F; Ehninger G; Lowenberg B; Dührsen U; Möröy T
Blood; 2010 Mar; 115(12):2462-72. PubMed ID: 20075157
[TBL] [Abstract][Full Text] [Related]
7. Presence of the
Vorwerk J; Sun K; Frank D; Neumann F; Hüve J; Budde PM; Liu L; Xie X; Patnana PK; Ahmed HMM; Opalka B; Lenz G; Jayavelu AK; Khandanpour C
Front Oncol; 2022; 12():903691. PubMed ID: 36003783
[TBL] [Abstract][Full Text] [Related]
8. Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications.
Möröy T; Khandanpour C
Front Oncol; 2019; 9():824. PubMed ID: 31508375
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis.
Khandanpour C; Eisfeld C; Nimmagadda SC; Raab MS; Weinhold N; Seckinger A; Hose D; Jauch A; Försti A; Hemminki K; Hielscher T; Hummel M; Lenz G; Goldschmidt H; Huhn S
Front Oncol; 2021; 11():757664. PubMed ID: 34760702
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
[TBL] [Abstract][Full Text] [Related]
11. The human GFI136N variant induces epigenetic changes at the Hoxa9 locus and accelerates K-RAS driven myeloproliferative disorder in mice.
Khandanpour C; Krongold J; Schütte J; Bouwman F; Vassen L; Gaudreau MC; Chen R; Calero-Nieto FJ; Diamanti E; Hannah R; Meyer SE; Grimes HL; van der Reijden BA; Jansen JH; Patel CV; Peeters JK; Löwenberg B; Dührsen U; Göttgens B; Möröy T
Blood; 2012 Nov; 120(19):4006-17. PubMed ID: 22932805
[TBL] [Abstract][Full Text] [Related]
12. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
13. Enforced GFI1 expression impedes human and murine leukemic cell growth.
Hönes JM; Thivakaran A; Botezatu L; Patnana P; Castro SVDC; Al-Matary YS; Schütte J; Fischer KBI; Vassen L; Görgens A; Dührsen U; Giebel B; Khandanpour C
Sci Rep; 2017 Nov; 7(1):15720. PubMed ID: 29147018
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of growth factor independence 1 expression in patients with
Salarpour F; Goudarzipour K; Mohammadi MH; Ahmadzadeh A; Faraahi S; Allahbakhshian A; Farsani MA
J Cancer Res Ther; 2020; 16(1):23-27. PubMed ID: 32362605
[TBL] [Abstract][Full Text] [Related]
15. miRNA-650 exerts anti-leukemia activity by inhibiting cell proliferation through Gfi1 targeting.
Yuan C; Xu L; Du P; Pang J
Tumori; 2018 Oct; 104(5):369-374. PubMed ID: 28574132
[TBL] [Abstract][Full Text] [Related]
16. Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy.
Uy GL; Duncavage EJ; Chang GS; Jacoby MA; Miller CA; Shao J; Heath S; Elliott K; Reineck T; Fulton RS; Fronick CC; O'Laughlin M; Ganel L; Abboud CN; Cashen AF; DiPersio JF; Wilson RK; Link DC; Welch JS; Ley TJ; Graubert TA; Westervelt P; Walter MJ
Leukemia; 2017 Apr; 31(4):872-881. PubMed ID: 27740633
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent expression of GFI1 alters metabolism in the haematopoietic progenitors and MLL::AF9-induced leukaemic cells.
Patnana PK; Liu L; Frank D; Nimmagadda SC; Behrens M; Ahmed H; Xie X; Liebmann M; Wei L; Gerdemann A; Thivakaran A; Humpf HU; Klotz L; Dugas M; Varghese J; Trajkovic-Arsic M; Siveke JT; Hanenberg H; Opalka B; Dührsen U; Reinhardt HC; Guenther U; von Bubnoff N; Khandanpour C
Br J Haematol; 2023 Sep; 202(5):1033-1048. PubMed ID: 37423893
[TBL] [Abstract][Full Text] [Related]
18. LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.
Barth J; Abou-El-Ardat K; Dalic D; Kurrle N; Maier AM; Mohr S; Schütte J; Vassen L; Greve G; Schulz-Fincke J; Schmitt M; Tosic M; Metzger E; Bug G; Khandanpour C; Wagner SA; Lübbert M; Jung M; Serve H; Schüle R; Berg T
Leukemia; 2019 Jun; 33(6):1411-1426. PubMed ID: 30679800
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
Wiggers CRM; Govers AMAP; Lelieveld D; Egan DA; Zwaan CM; Sonneveld E; Coffer PJ; Bartels M
Pediatr Blood Cancer; 2019 Aug; 66(8):e27785. PubMed ID: 31044544
[TBL] [Abstract][Full Text] [Related]
20. GFI1 is required for
Marneth AE; Botezatu L; Hönes JM; Israël JCL; Schütte J; Vassen L; Lams RF; Bergevoet SM; Groothuis L; Mandoli A; Martens JHA; Huls G; Jansen JH; Dührsen U; Berg T; Möröy T; Wichmann C; Lo MC; Zhang DE; van der Reijden BA; Khandanpour C
Haematologica; 2018 Sep; 103(9):e395-e399. PubMed ID: 29674496
[No Abstract] [Full Text] [Related]
[Next] [New Search]
